Frontiers Editorial Office*
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
A Retraction of the Original Research article
Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling
by Yi Y-C, Liang R, Chen X-Y, Fan H-N, Chen M, Zhang J and Zhu J-S (2021). Front. Oncol. 11:768879. doi: 10.3389/fonc.2021.768879
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors do not agree to this retraction.
Citation: Frontiers Editorial Office (2025) Retraction: Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling. Front. Oncol. 15:1591122. doi: 10.3389/fonc.2025.1591122
Received: 11 March 2025; Accepted: 11 March 2025;
Published: 25 March 2025.
Approved by:
Giuseppe Giaccone, Cornell University, United StatesCopyright © 2025 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==